Holzer & Holzer Reminds Investors of April 6 Deadline for Lead Plaintiff in Class Action Lawsuits

Lawsuits target BlackRock TCP Capital, Mereo BioPharma, POMDOCTOR, and Ultragenyx Pharmaceutical

Mar. 14, 2026 at 3:34pm

Got story updates? Submit your updates here. ›

Holzer & Holzer, LLC, a securities litigation law firm, is reminding investors of the April 6, 2026 deadline to seek to be appointed lead plaintiff in class action lawsuits against BlackRock TCP Capital Corp., Mereo BioPharma Group plc, POMDOCTOR LIMITED, and Ultragenyx Pharmaceutical Inc. The lawsuits allege the companies made materially false and/or misleading statements and/or failed to disclose material facts during specified time periods, resulting in significant investor losses.

Why it matters

These class action lawsuits represent efforts by shareholders to hold public companies accountable for alleged misconduct that impacted their investments. The deadlines to join the lawsuits as lead plaintiffs are approaching, giving investors an opportunity to potentially recoup losses if the cases are successful.

The details

The lawsuits allege the following: BlackRock TCP Capital Corp. (TCPC): Defendants made false/misleading statements and/or failed to disclose material facts about the timely and appropriate valuation of the company's investments between November 6, 2024 and January 23, 2026. Mereo BioPharma Group plc (MREO): Defendants made false/misleading statements and/or failed to disclose material facts about setrusumab's ability to achieve statistical significance for primary endpoints in ORBIT and COSMIC studies between June 5, 2023 and December 26, 2025. POMDOCTOR LIMITED (POM): Defendants engaged in an alleged fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals between October 9, 2025 and December 11, 2025. Ultragenyx Pharmaceutical Inc. (RARE): Defendants made false/misleading statements and/or failed to disclose material facts about the company's expected results for its Phase III Orbit and Cosmic Studies between August 3, 2023 and December 26, 2025.

  • The deadline to ask the court to be appointed lead plaintiff in the BlackRock TCP Capital, Mereo BioPharma, POMDOCTOR, and Ultragenyx Pharmaceutical cases is April 6, 2026.

The players

Holzer & Holzer, LLC

A securities litigation law firm that is representing shareholders in these class action lawsuits.

BlackRock TCP Capital Corp.

A publicly traded investment management firm that is the defendant in one of the class action lawsuits.

Mereo BioPharma Group plc

A publicly traded biopharmaceutical company that is the defendant in one of the class action lawsuits.

POMDOCTOR LIMITED

A publicly traded company that is the defendant in one of the class action lawsuits, accused of an alleged fraudulent stock promotion scheme.

Ultragenyx Pharmaceutical Inc.

A publicly traded biopharmaceutical company that is the defendant in one of the class action lawsuits.

Got photos? Submit your photos here. ›

What they’re saying

“If you purchased BlackRock TCP, Mereo, Pomdoctor, or Ultragenyx shares during the specified time periods and suffered a significant loss, you are encouraged to discuss your legal rights.”

— Corey D. Holzer, Attorney, Holzer & Holzer, LLC (Holzer & Holzer, LLC)

The takeaway

These class action lawsuits represent an opportunity for investors who suffered losses to potentially recoup some of those losses if the cases are successful. The deadlines to join as lead plaintiffs are approaching, so affected investors should act quickly to understand their legal options.